Prediction of 5-year Progression-free Survival in Advanced Nasopharyngeal Carcinoma with Pretreatment PET/CT Using Multi-modality Deep Learning-based Radiomics
Overview
Affiliations
Objective: Deep learning-based radiomics (DLR) has achieved great success in medical image analysis and has been considered a replacement for conventional radiomics that relies on handcrafted features. In this study, we aimed to explore the capability of DLR for the prediction of 5-year progression-free survival (PFS) in advanced nasopharyngeal carcinoma (NPC) using pretreatment PET/CT images.
Methods: A total of 257 patients (170/87 patients in internal/external cohorts) with advanced NPC (TNM stage III or IVa) were enrolled. We developed an end-to-end multi-modality DLR model, in which a 3D convolutional neural network was optimized to extract deep features from pretreatment PET/CT images and predict the probability of 5-year PFS. The TNM stage, as a high-level clinical feature, could be integrated into our DLR model to further improve the prognostic performance. For a comparison between conventional radiomics and DLR, 1,456 handcrafted features were extracted, and optimal conventional radiomics methods were selected from 54 cross-combinations of six feature selection methods and nine classification methods. In addition, risk group stratification was performed with clinical signature, conventional radiomics signature, and DLR signature.
Results: Our multi-modality DLR model using both PET and CT achieved higher prognostic performance (area under the receiver operating characteristic curve (AUC) = 0.842 ± 0.034 and 0.823 ± 0.012 for the internal and external cohorts) than the optimal conventional radiomics method (AUC = 0.796 ± 0.033 and 0.782 ± 0.012). Furthermore, the multi-modality DLR model outperformed single-modality DLR models using only PET (AUC = 0.818 ± 0.029 and 0.796 ± 0.009) or only CT (AUC = 0.657 ± 0.055 and 0.645 ± 0.021). For risk group stratification, the conventional radiomics signature and DLR signature enabled significant difference between the high- and low-risk patient groups in both the internal and external cohorts ( < 0.001), while the clinical signature failed in the external cohort ( = 0.177).
Conclusion: Our study identified potential prognostic tools for survival prediction in advanced NPC, which suggests that DLR could provide complementary values to the current TNM staging.
Wu B, Chen X, Cao C Curr Oncol Rep. 2025; .
PMID: 39998781 DOI: 10.1007/s11912-025-01651-9.
Meng M, Gu B, Fulham M, Song S, Feng D, Bi L NPJ Precis Oncol. 2024; 8(1):232.
PMID: 39402129 PMC: 11473954. DOI: 10.1038/s41698-024-00690-y.
Tong X, Wang S, Zhang J, Fan Y, Liu Y, Wei W Bioengineering (Basel). 2024; 11(1).
PMID: 38247927 PMC: 10813496. DOI: 10.3390/bioengineering11010050.
Rogasch J, Shi K, Kersting D, Seifert R Nuklearmedizin. 2023; 62(6):361-369.
PMID: 37995708 PMC: 10667066. DOI: 10.1055/a-2198-0545.
Gu B, Meng M, Xu M, Feng D, Bi L, Kim J Eur J Nucl Med Mol Imaging. 2023; 50(13):3996-4009.
PMID: 37596343 PMC: 10611876. DOI: 10.1007/s00259-023-06399-7.